-

Covalon Postpones Annual Meeting of Shareholders Due to COVID-19

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, announces today that given the extraordinary circumstances of the ongoing COVID-19 pandemic and the resulting restrictions on public gatherings, it is postponing its annual meeting of shareholders to a later date.

The Company is assessing its options to hold a virtual meeting with a view to protecting the health and safety of its employees, shareholders, and other usual meeting attendees. As a result, the current meeting and record dates are cancelled. The updated record date and date of the annual meeting of shareholders will be communicated when known.

About Covalon
Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events, including the Company’s annual meeting of shareholders. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including risks related to the COVID-19 virus and the government response that may affect the annual meeting of shareholders, the ability of the Company to digitally host the annual meeting of shareholders, the ability of necessary personnel to attend to the administration of the annual meeting of shareholders due to mandated quarantine or COVID-19 related restrictions and other risks, any of which could cause future events to differ materially from those discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Contacts

Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

Covalon Technologies Ltd.

OTCQX:CVALF
Details
Headquarters: Mississauga, Canada
CEO: Brent Ashton
Employees: 80
Organization: PUB

Release Versions

Contacts

Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon

Social Media Profiles
More News From Covalon Technologies Ltd.

Covalon Reports Fiscal 2026 Third Quarter Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 third quarter results for the period ended June 30, 2026. Full financial statements and management’s discussion and analysis are available on the Company’s profile at www.sedarplus.ca. Brent Ashton, Covalon’s Chief Executive Officer, commented, “Covalon’s third quarter of fiscal 2026 delivered outstandi...

Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2026 Results

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q3 Fiscal 2026 results on Thursday, August 27, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, August 27, 2026, at 8:30am ET. To view, listen to, and participate in the live webcast, please follow the link below: https://events.q4inc.com/attendee/768174807 To l...

Covalon Announces Appointment of New Director and DSU Grants

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the appointment of Dr. Murray Miller to its Board of Directors (“Board”) as an independent director subject to TSX Venture Exchange approval. Dr. Miller graduated as a Medical Doctor from the University of Manitoba in 1982. He completed his residency in Radiology at the University of Toronto. Dr. Miller has served as a...
Back to Newsroom